The African-American heart failure trial: Background, rationale and significance

Anne L. Taylor, Jay N. Cohn, Manuel Worcel, Joseph A. Franciosa

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


New treatments have improved outcomes in heart failure (HF), but applicability of these advances may be limited in African Americans. Analysis of previous trials has shown that a combination of hydralazine (H) plus isosorbide dinitrate (ISDN) may be especially beneficial in African Americans with HF. The African American Heart Failure Trial (A-HeFT) is a double-blind, randomized, and placebo-controlled trial in African American patients with stable NYHA Class III-IV HF while on standard therapy. Randomization to addition of BiDil®, a fixed combination of H + ISDN, or placebo, will be stratified for beta-blocker usage, and all patients will be treated and followed until the last patient entered has completed six months of follow-up. The primary efficacy endpoint will be a composite score including quality of life, deaths, and hospitalizations for HF. At least 600 patients will be randomized. The first patient was randomized in June, 2001. Besides additional testing of H+ISDN in HF, A-HeFT will be the first HF trial aimed at a subgroup of African American patients, as well as the first to use a new composite HF score as its primary efficacy endpoint.

Original languageEnglish (US)
Pages (from-to)762-769
Number of pages8
JournalJournal of the National Medical Association
Issue number9
StatePublished - Sep 1 2002


  • Heart failure
  • Hydralazine
  • Isosorbide dinitrate
  • Vasodilators


Dive into the research topics of 'The African-American heart failure trial: Background, rationale and significance'. Together they form a unique fingerprint.

Cite this